Eupraxia Pharmaceuticals Inc. (EPRX) Statistics & Valuation Metrics - Stocknear

Eupraxia Pharmaceuticals ...

NASDAQ: EPRX · Real-Time Price · USD
5.30
-0.06 (-1.12%)
At close: Sep 05, 2025, 11:36 AM

Eupraxia Pharmaceuticals Statistics

Share Statistics

Eupraxia Pharmaceuticals has 35.94M shares outstanding. The number of shares has increased by 0.64% in one year.

35.94M
0.64%
0%
n/a
27.79M
6,763
58.24%

Short Selling Information

The latest short interest is 170.77K, so 0% of the outstanding shares have been sold short.

170.77K
n/a
n/a
25.94

Valuation Ratios

The PE ratio is -2.89 and the forward PE ratio is -6.15. Eupraxia Pharmaceuticals's PEG ratio is 0.09.

-2.89
-6.15
0
16.9
0
0
0.09
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Eupraxia Pharmaceuticals.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 11.1, with a Debt / Equity ratio of 0.

11.1
11.1
0
-1.86
n/a
0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-1.11K
33
0
n/a

Taxes

n/a
0%

Stock Price Statistics

The stock price has increased by 115.32% in the last 52 weeks. The beta is 1.54, so Eupraxia Pharmaceuticals's price volatility has been higher than the market average.

1.54
115.32%
5.34
3.98
52.79
11,612

Income Statement

n/a
n/a
-39.04K
-36.66K
-38.66K
-38.82K
-1.1
Full Income Statement

Balance Sheet

The company has 33.1M in cash and 71.86K in debt, giving a net cash position of 33.03M.

33.1M
71.86K
33.03M
-131M
23.6M
20.21M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -29.99M and capital expenditures -104.23K, giving a free cash flow of -30.1M.

-29.99M
-104.23K
-30.1M
-901.89
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

EPRX does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for EPRX is $11, which is 106% higher than the current price. The consensus rating is "Buy".

$11
106%
Buy
2
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

32.42
1